Biotech Values

[DewDiligence]

It looks like SGP may be angling for a second-line
HCV label in the U.S. (to complement the second-
line label Peg-Intron already has in Europe). From
today’s PR:

http://biz.yahoo.com/prnews/061024/nytu046.html?.v=70

>>
Among the key presentations [at AASLD] will be data from the EPIC3 (Evaluation of PEG-INTRON in Control of Hepatitis C Cirrhosis) study, a large, prospective, controlled clinical trial designed to assess the safety and efficacy of PEG- INTRON and REBETOL in retreating patients who failed previous alpha interferon and ribavirin combination therapies, including peginterferon-based combination therapies.

Investigators for WIN-R (Weight-Based Dosing of PEG-INTRON and REBETOL), the largest community-based clinical study in hepatitis C ever conducted in the United States, will present results in patient populations traditionally considered hard to treat, including elderly patients and Hispanic patients.
<<